The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin

被引:49
作者
Becker, RHA
Frick, AD
Sha, S
Fountaine, RJ
机构
[1] Aventis Pharma Deutschland, Clin Discovery & Human Pharmacol, D-65926 Frankfurt, Germany
[2] Pfizer Global Res & Dev, Groton, CT USA
关键词
D O I
10.2337/diacare.29.02.06.dc05-1913
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To assess the absorption profile of inhaled insulin in healthy, actively smoking subjects at baseline, after smoking cessation, and after smoking resumption and compare it with nonsmoking subjects. RESEARCH DESIGN AND METHODS - Insulin pharmacokinetics and glucodynamics were measured in 20 male smoking subjects (10 - 20 cigarettes/day) and 10 matched nonsmoking subjects after receiving inhaled insulin (1 mg) or the approximate subcutaneous insulin equivalent (3 units) in a randomized cross-over fashion. All smokers then received inhaled insulin 12 h, 3 days, and 7 days into a smoking cessation period. They then resumed smoking for 2 - 3 days before again receiving inhaled insulin I h after the last cigarette. RESULTS - Before smoking cessation, maximum insulin concentration (C-max) and area under the curve (AUC) for insulin concentration time (AUC-Insulin(0-360)) with inhaled insulin were higher, and time to C-max (t(max)) shorter, in smokers than nonsmokers (C-max 26.8 vs. 9.7 mu U/ml; AUC-Insulin(0-360) 2,583 vs. 1,645 mu U (.) ml(-1) (.) min(-1); t(max) 20 vs. 53 min, respectively; all P < 0.05), whereas with subcutaneous insulin, systemic exposure was unchanged (AUC-Insulin(0-360) 2,324 vs. 2,269 mu U (.) ml(-1) (.) min(-1); P = NS). After smoking cessation, AUC-Insuln(0-360) decreased with inhaled insulin by up to 50% within 1 week and approached nonsmoker levels. C-max decreased and t(max) increased relative to baseline but were still not comparable with nonsmoker values. Smoking resumption completely reversed the effect of smoking cessation. Glucodynamics corroborated the observed findings in insulin pharmacokinetics. CONCLUSIONS - Cessation and resumption of smoking greatly altered the pharmacokinetics of inhaled insulin. As rapid changes in systemic insulin exposure increase hypoglycemia risk, inhaled insulin should not be used in people with diabetes who choose to continue smoking. This is consistent with recommendations that people With diabetes refrain from smoking altogether.
引用
收藏
页码:277 / 282
页数:6
相关论文
共 26 条
  • [1] American Diabetes Association, 2004, DIABETES CARE S1, V27, pS74
  • [2] Nicotine infusion acutely impairs insulin sensitivity in type 2 diabetic patients but not in healthy subjects
    Axelsson, T
    Jansson, PA
    Smith, U
    Eliasson, B
    [J]. JOURNAL OF INTERNAL MEDICINE, 2001, 249 (06) : 539 - 544
  • [3] Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise - A 12-week, randomized, comparative trial
    DeFronzo, RA
    Bergenstal, RM
    Cefalu, WT
    Pullman, J
    Lerman, S
    Bode, BW
    Phillips, LS
    [J]. DIABETES CARE, 2005, 28 (08) : 1922 - 1928
  • [4] Cigarette smoking and diabetes
    Eliasson, B
    [J]. PROGRESS IN CARDIOVASCULAR DISEASES, 2003, 45 (05) : 405 - 413
  • [5] Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes
    Freemantle, N
    Blonde, L
    Duhot, D
    Hompesch, M
    Eggertsen, R
    Hobbs, FDR
    Martinez, L
    Ross, S
    Bolinder, B
    Stridde, E
    [J]. DIABETES CARE, 2005, 28 (02) : 427 - 428
  • [6] Smoking and diabetes
    Haire-Joshu, D
    Glasgow, RE
    Tibbs, TL
    [J]. DIABETES CARE, 1999, 22 (11) : 1887 - 1898
  • [7] The impact of smoking on inhaled insulin
    Himmelmann, A
    Jendle, J
    Mellén, A
    Petersen, AH
    Dahl, UL
    Wollmer, P
    [J]. DIABETES CARE, 2003, 26 (03) : 677 - 682
  • [8] Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes - Results of a 6-month, randomized, comparative trial
    Hollander, PA
    Blonde, L
    Rowe, R
    Mehta, AE
    Milburn, JL
    Hershon, KS
    Chiasson, JL
    Levin, SR
    [J]. DIABETES CARE, 2004, 27 (10) : 2356 - 2362
  • [9] *INT DIAB FED, DIAB TOB US HARMF CO
  • [10] JONES JG, 1980, LANCET, V1, P66